National Cancer Institute (nci)

This early-stage study tested two chemotherapy drugs, pevonedistat and belinostat, in 18 adults with acute myeloid leukemia or myelodysplastic syndrome that returned or didn't respond to prior therapy. The main goal was to find the safest dose and identify side effects. The trial…

This study tested a drug called sacituzumab govitecan in people whose ovarian, endometrial, or cervical cancer returned after at least two rounds of standard treatment. Participants received the drug through an IV on days 1 and 8 of each 21-day cycle. The goal was to see if the d…

This study tested an experimental drug called zotiraciclib (TG02) combined with the standard chemotherapy temozolomide in adults with recurrent anaplastic astrocytoma or glioblastoma. The goal was to find safe doses and see if the combination works better than temozolomide alone.…

This early-phase study tested a gene therapy for people with advanced cancer that produces a protein called CEA. Researchers took patients' own immune cells, added a new gene to help them attack CEA-making cancer cells, and infused them back after chemotherapy. Only 3 patients we…

This study tested whether adding the immunotherapy drug nivolumab to standard chemotherapy could help people with nasopharyngeal cancer that has returned or spread. The trial was stopped early after enrolling only 15 participants, so we don't have clear results on whether the com…

This study tested a new treatment that takes a patient's own immune cells, modifies them in a lab to recognize and attack cancer cells with a specific marker (KK-LC-1), and gives them back. It was for adults with advanced stomach, breast, cervical, lung, or other epithelial cance…

This study tested two antibody drugs, magrolimab and mogamulizumab, together in people with advanced T-cell lymphoma (mycosis fungoides or Sezary syndrome) that had returned or stopped responding to treatment. The goal was to find the safest dose and see if the combination could …

This study tested the cancer drug olaparib in people with a rare type of pancreatic cancer called pancreatic acinar cell carcinoma (PACC). The goal was to see if olaparib could shrink tumors or stop them from growing. Only 5 adults whose cancer had not responded to prior treatmen…

This study tested a drug called SGI-110 (guadecitabine) in people aged 12 and older with rare cancers like wild-type GIST, pheochromocytoma, paraganglioma, or HLRCC-related kidney cancer that had not responded to other treatments. The goal was to see if the drug could shrink tumo…

This study tested a drug called BMS-986253 for people with myelodysplastic syndromes (MDS), a group of bone marrow cancers. The goal was to see if the drug was safe and could help control the disease. Only 2 adults enrolled before the study was stopped early, so no conclusions ab…

This early-phase study aimed to find the best dose and test the safety of combining dasatinib (a targeted cancer drug) with icosapent ethyl (an omega-3 fatty acid) in people with metastatic triple-negative inflammatory breast cancer, a rare and aggressive form. Only one participa…

This study tested two oral drugs, eltanexor and Inqovi, in adults with high-risk myelodysplastic syndromes (MDS) that did not improve with standard treatment. The goal was to find the best dose and see if the combination could control the disease. Only 3 people enrolled before th…